Chiesi Farmaceutici SpA & Cornerstone Therapeutics Announce Merger Transaction

Chiesi Farmaceutici S.p.A. and Cornerstone Therapeutics Inc. recently announced that the special committee of the Cornerstone Board of Directors, as well as the boards of directors of both companies, have approved a definitive merger agreement under which Chiesi will acquire all of the outstanding common shares of Cornerstone for $9.50 per share in cash. Chiesi currently owns 58% of Cornerstone’s outstanding common shares.
The transaction represents a premium of approximately 78% over Cornerstone’s closing price of $5.35 on February 15, 2013, the last trading day prior to Chiesi’s initial written proposal, and a premium of approximately 42% to the high end of the range of Chiesi’s initial proposal.

The transaction advances Chiesi’s initiative to build a larger global presence and represents a significant step toward strengthening its presence in the US. The acquisition creates a foundation for new projects in special care and respiratory disorders and will provide a sales channel on all products Chiesi intends to commercialize in the US. Through this transaction, Chiesi will become a bigger player in special care in the US, the world’s largest market for this type of care (approximately 50% of projects in orphan drugs originate in the US). Chiesi has a strong product pipeline, including highly promising molecules for the treatment of respiratory and rare diseases, and will continue to develop its pipeline as it consolidates its presence in the US.

The transaction positions Cornerstone for long-term growth and development as a private company and affords a level of financial flexibility required to enhance Cornerstone’s product pipeline, strengthen its marketing network, and allow it to capitalize on additional opportunities to acquire high-quality respiratory products.

“We are excited to announce this transaction, which offers immediate and significant cash value to Cornerstone stockholders, and creates enhanced flexibility for Cornerstone to grow and prosper in the global marketplace,” said Ugo Di Francesco, Chief Executive Officer of Chiesi. “With the support of Chiesi, Cornerstone will help fulfill its mission to develop and commercialize innovative pharmaceutical solutions to improve the quality of human life. We will continue to promote Cornerstone’s market leading respiratory products, as we establish a strong footprint in the special care market. We look forward to working closely with the Cornerstone management team and to welcoming its talented employees to the Chiesi family.”

“Together with Chiesi, we have made significant progress in transforming Cornerstone into a market leader in our core therapeutic area of hospital and related specialty products and expect enhanced development opportunities through this exciting transaction,” added Craig Collard, CEO, and Chairman of Cornerstone. “We are pleased to be able to provide employees with additional opportunities and customers with added benefits as part of a global company. Cornerstone has a solid foundation, and we believe this is a natural step forward to achieve long-term success.”

Mr. Collard, who beneficially owns approximately 6% of Cornerstone’s outstanding shares, has entered into a voting agreement pursuant to which he has agreed to vote all of his shares in favor of the transaction.

The transaction is expected to be completed in the first quarter of 2014, subject to the satisfaction of certain conditions, including the approval of a majority of Cornerstone’s stockholders other than Chiesi and other than Cornerstone’s officers and directors, and subject to other customary closing conditions. The companies believe that the transaction is not subject to clearance under the Hart-Scott-Rodino (HSR) Antitrust Improvements Act of 1976. These and other considerations will be set forth in greater detail in the merger agreement filed as an exhibit on the Form 8-K that Cornerstone will file with the U.S. Securities and Exchange Commission.

Founded in 1935 in Parma, Italy, Chiesi Farmaceutici currently has 25 affiliates worldwide and markets its therapeutics in over 60 countries. For more information, visit www.chiesigroup.com.

Cornerstone Therapeutics Inc., headquartered in Cary, NC, is a specialty pharmaceutical company focused on commercializing products for the hospital and adjacent specialty markets. For more information, visit www.crtx.com.